Research Article

Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes

* Author for correspondence

Email the corresponding author at d.hein@louisville.edu

Department of Pharmacology & Toxicology, University of Louisville Health Sciences Center, 505 South Hancock Street, Clinical & Translational Research Building Room 303, Louisville, KY 40202-1617, USA

Search for more papers by this author

Published Online:19 Dec 2011https://doi.org/10.2217/pgs.11.122

View article

Abstract

Aim: Humans exhibit genetic polymorphism in NAT2 resulting in rapid, intermediate and slow acetylator phenotypes. Over 65 NAT2 variants possessing one or more SNPs in the 870-bp NAT2 coding region have been reported. The seven most frequent SNPs are rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A). The majority of studies investigate the NAT2 genotype assay for three SNPs: 481C>T, 590G>A and 857G>A. A tag-SNP (rs1495741) recently identified in a genome-wide association study has also been proposed as a biomarker for the NAT2 phenotype. Materials & methods: Sulfamethazine N-acetyltransferase catalytic activities were measured in cryopreserved human hepatocytes from a convenience sample of individuals in the USA with an ethnic frequency similar to the 2010 US population census. These activities were segregated by the tag-SNP rs1495741 and each of the seven SNPs described above. We assessed the accuracy of the tag-SNP and various two-, three-, four- and seven-SNP genotyping panels for their ability to accurately infer NAT2 phenotype. Results: The accuracy of the various NAT2 SNP genotype panels to infer NAT2 phenotype were as follows: seven-SNP: 98.4%; tag-SNP: 77.7%; two-SNP: 96.1%; three-SNP: 92.2%; and four-SNP: 98.4%. Conclusion: A NAT2 four-SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C), rs1799930 (590G>A) and rs1799931 (857G>A) infers NAT2 acetylator phenotype with high accuracy, and is recommended over the tag-, two-, three- and (for economy of scale) the seven-SNP genotyping panels, particularly in populations of non-European ancestry.

Original submitted 9 June 2011; Revision submitted 9 August 2011

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br. Med. J.2,485–491 (1960).
Medline CASGoogle Scholar
2 Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol. Rev.37,25–79 (1985).
Medline CASGoogle Scholar
3 Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev.31,489–502 (1999).
Medline CASGoogle Scholar
4 Blum M, Demierre A, Grant DM, Heim, M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl Acad. Sci. USA88,5237–5241 (1991).▪ Described the initial report into the functional effects of three common NAT2 SNPs and formed the basis for the historical three-SNP assay.
Medline CASGoogle Scholar
5 Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl Acad. Sci. USA88,6333–6337 (1991).
Medline CASGoogle Scholar
6 Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab. Rev.37,511–564 (2005).
Medline CASGoogle Scholar
7 Grant DM, Goodfellow GH, Sugamori K, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology61,204–211 (2000).
Medline CASGoogle Scholar
8 Sim E, Lack N, Wang CJ et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology254,170–183 (2008).
Medline CASGoogle Scholar
9 Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev.9,29–42 (2000).▪ One of the first comprehensive reviews on the role of NAT2 polymorphisms in cancer risk. The paper also discusses possible genotyping misclassification with the historical three-SNP genotype assay.
Medline CASGoogle Scholar
10 Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab.9,520–531 (2008).
Medline CASGoogle Scholar
11 Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr. Drug Metab.9,471–486 (2008).
Medline CASGoogle Scholar
12 Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin. Drug Metab. Toxicol.5,353–366 (2009).▪ Summarizes the functional effects of NAT2 SNPs.
Medline CASGoogle Scholar
13 Deitz AC, Rothman N, Rebbeck TR et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol. Biomarkers Prev.13,1543–1546 (2004).▪ Reports NAT2 genotyping misclassification with the historical three-SNP assay and the consequences for gene–environmental interaction analyses.
Medline CASGoogle Scholar
14 Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem.231,413–420 (1995).
Medline CASGoogle Scholar
15 Rothman N, Garcia-Closas M, Chatterjee N et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet.42,978–984 (2010).▪▪ Describes the genome-wide association study that identified a new tag-SNP for slow acetylation and increased risk for urinary bladder cancer.
Medline CASGoogle Scholar
16 Garcia-Closas M, Hein DW, Silverman D et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet. Genomics21,231–236 (2011).▪▪ Reported associations between the newly identified tag-SNP and arylamine N-acetyltransferase activities in human hepatocytes from a population of individuals of European ancestry.
Medline CASGoogle Scholar
17 Doll MA, Zang Y, Moeller T, Hein DW. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J. Pharmacol. Exp. Ther.334,540–544 (2010).
Medline CASGoogle Scholar
18 Doll MA, Hein, DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal. Biochem.288,106–108 (2001).
Medline CASGoogle Scholar
19 Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene25,1649–1658 (2006).
Medline CASGoogle Scholar
20 Leff MA, Epstein PN, Doll MA et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther.290,182–187 (1999).
Medline CASGoogle Scholar
21 Chapron DJ, Kramer PA, Mercik SA. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin. Pharmacol. Ther.27,104–113 (1980).
Medline CASGoogle Scholar
22 Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur. J. Clin. Pharmacol.62,355–359 (2006).
Medline CASGoogle Scholar
23 Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem.265,12757–12760 (1990).
Medline CASGoogle Scholar
24 Parkin DP, Vandenplas S, Botha FJ et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med.155,1717–1722 (1997).
Medline CASGoogle Scholar
25 Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J. Med. Genet.34,758–760 (1997).
Medline CASGoogle Scholar
26 Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother.49,1733–1738 (2005).▪ Describes the importance of NAT2 genotyping in tuberculosis therapy.
Medline CASGoogle Scholar
27 Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin. Chim. Acta407,30–35 (2009).
Medline CASGoogle Scholar
28 Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol.17,459–464 (1984).
Medline CASGoogle Scholar
29 Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet.57,581–592 (1995).
Medline CASGoogle Scholar
30 Hein DW, Trinidad A, Yerokun T, Ferguson RJ, Kirlin WG, Weber WW. Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. Drug Metab. Dispos.16,341–347 (1988).
Medline CASGoogle Scholar
31 Hein DW, Rustan TD, Bucher KD, Miller LS. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian-hamsters congenic at the polymorphic acetyltransferase locus. J. Pharmacol. Exp. Ther.259,699–704 (1991).
Medline CASGoogle Scholar
32 Hein DW, Doll MA, Rustan TD, Gray K, Ferguson RJ, Feng Y. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol.124,16–24 (1994).
Medline CASGoogle Scholar
33 Hein DW, Rustan TD, Bucher KD, Martin WJ, Furman EJ. Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver. Drug Metab. Dispos.19,933–937 (1991).
Medline CASGoogle Scholar
34 Hein DW, Bendaly J, Neale JR, Doll MA. Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat. Drug Metab. Dispos.36,2452–2459 (2008).
Medline CASGoogle Scholar
35 Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol.39,184–191 (1991).
Medline CASGoogle Scholar
36 Hein DW, Doll MA, Rustan TD et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis14,1633–1638 (1993).
Medline CASGoogle Scholar
37 Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet.3,729–734 (1994).
Medline CASGoogle Scholar
38 Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res.55,3531–3536 (1995).
Medline CASGoogle Scholar
39 Grant DM, Hughes NC, Janezic SA et al. Human acetyltransferase polymorphisms. Mutat. Res.376,61–70 (1997).
Medline CASGoogle Scholar
40 Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics11,207–215 (2001).
Medline CASGoogle Scholar
41 Hein DW, Fretland AJ Doll MA. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int. J. Cancer119,1208–1211 (2006).
Medline CASGoogle Scholar
42 Zang Y, Zhao S, Doll MA, States JC, Hein DW. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics14,717–723 (2004).
Medline CASGoogle Scholar
43 Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis28,1665–1671 (2007).
Medline CASGoogle Scholar
44 Selinski S, Blaszkewicz M, Lehmann ML et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet. Genomics21(10),673–678 (2011).
Medline CASGoogle Scholar
45 Loktionov A, Moore W, Spencer SP et al. Differences in N-acetylation genotypes between Caucasians and black South Africans: implications for cancer prevention. Cancer Detect. Prev.26,15–22 (2002).
Medline CASGoogle Scholar
46 Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet.9,21 (2008).
MedlineGoogle Scholar
47 Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS ONE6,e18507 (2011).
Medline CASGoogle Scholar
48 Ohno M, Yamaguchi I, Yamamoto I et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis.4,256–261 (2000).
Medline CASGoogle Scholar
49 Hiratsuka M, Kishikawa Y, Takekuma Y et al. Genotyping of the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet.17,357–362 (2002).
Medline CASGoogle Scholar
50 Cho HJ, Koh WJ, Ryu YJ et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis87,551–556 (2007).
Medline CASGoogle Scholar
51 Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature466,7071–7073 (2010).
Google Scholar
101 University of Louisville, KY, USA. Department of pharmacology and toxicology. www.n-acetyltransferasenomenclature.louisville.edu▪▪ Official website for consensus human arylamine N-acetyltransferase gene nomenclature.
Google Scholar
102 Celsis. Characterization tables. www.celsis.com/ivt/characterization-tables/
Google Scholar
103 US Census Burea. Overview of race and Hispanic origin: 2010. www.census.gov/prod/cen2010/briefs/c2010br-02.pdf
Google Scholar

Vol. 13, No. 1

Metrics

Downloaded 368 times

History

Published online 19 December 2011

Published in print January 2012

Information

Keywords

Financial & competing interests disclosure

This research project was supported by National Institute of Health grants R01-CA034627 and P30-ES014443. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download